The Chronically Comorbid Employee: When the Plan Is Designed for Events and the Member Has Conditions

Three in four American adults have at least one chronic condition. More than half have two or more. Among midlife adults aged 35 to 64 (the working-age core of the small employer market), 78.4 percent reported one or more chronic conditions in the CDC’s 2023 Behavioral Risk Factor Surveillance System data, a figure that increased by 7 percentage points among young adults from 2013 to 2023. Chronic diseases drive $4.9 trillion in annual health care costs nationally. The employee managing type 2 diabetes, hypertension, and obesity simultaneously is not an outlier. They are the median. The standard level funded plan was not designed for this employee. It was designed for the acute event: the emergency room visit, the surgery, the hospitalization. The chronically comorbid employee does not need the plan for events. They need it every month, for medications that prevent events, for the physician relationship that manages the trajectory, and for the cost-sharing structure that does not punish adherence. The standard plan punishes adherence.

The Deductible Wall

#

The standard level funded plan with a $2,000 to $3,000 individual deductible imposes the full cost of routine maintenance on the chronically comorbid employee until the deductible clears. A diabetic employee on metformin, lisinopril, and a statin fills three prescriptions every 30 days. At retail pricing before the deductible clears, the monthly pharmacy cost is $40 to $400 depending on whether generics are available and whether the pharmacy is in-network. An employee earning $42,000 annually (the median income range for a non-supervisory worker at a small employer) cannot absorb $200 per month in pharmacy costs in January, February, and March while the deductible accumulates. The consequence is prescription non-adherence: skipped doses, unfilled prescriptions, rationing behavior that extends a 30-day supply to 45 or 60 days.

The RAND Health Insurance Experiment, the foundational study of cost-sharing’s effect on health care utilization published by Manning et al. in 1987, demonstrated that cost-sharing reduces both necessary and unnecessary care proportionally, and that the reduction in necessary care is most harmful for lower-income individuals with chronic conditions. The finding has been confirmed repeatedly in subsequent research. The self-funded employer whose plan design imposes a deductible on maintenance medications for chronic conditions is not managing costs. They are deferring costs to a more expensive point in the disease trajectory. The diabetic employee who stops taking metformin because of cost-sharing in Q1 presents with uncontrolled A1c in Q3 and generates an emergency department visit, a hospitalization, or a stop-loss-level claim in Q4. The plan paid nothing for the $40-per-month generic that would have prevented the $85,000 inpatient admission. The math is not ambiguous.

What the Employer Controls

#

The self-funded employer controls plan design in ways the fully insured employer in this market does not. Three specific design decisions change the chronically comorbid employee’s experience and the plan’s cost trajectory.

First, zero-deductible carve-outs for chronic disease medications. The employer can designate specific drug classes (diabetes medications, antihypertensives, statins, antidepressants, maintenance inhalers for asthma and COPD) as covered at zero cost-sharing regardless of deductible status. The plan document specifies the carve-out. The TPA implements it in the claims adjudication logic. This is a plan design decision, not a carrier decision. The ACA already requires coverage of certain preventive medications without cost-sharing; the employer who extends that principle to maintenance medications for diagnosed chronic conditions is applying the same logic to a broader formulary. Most small level funded plan sponsors have never been told this option exists.

Second, DPC as the coordination anchor for comorbid care. A DPC physician managing a diabetic, hypertensive, obese patient has time. The DPC practice model with panels of 400 to 600 patients (rather than the conventional 2,000 to 2,500) produces 30- to 60-minute appointments, proactive outreach between visits, and the physician relationship that chronic disease management requires. The employer who adds DPC membership at $75 to $150 per member per month alongside the level funded plan creates a primary care infrastructure that the level funded plan alone cannot provide. The DPC physician adjusts medications in real time, monitors adherence through direct patient contact, and identifies complications before they generate claims. The plan economics improve because the primary care relationship exists outside the claims system.

Third, structured disease management programs with published outcome data. Several TPA-adjacent vendors (Omada Health for diabetes prevention, Virta Health for type 2 diabetes reversal, Livongo by Teladoc for chronic condition monitoring) provide evidence-based programs that the employer can embed as covered benefits with financial incentives structured within HIPAA wellness program rules under 26 C.F.R. Section 54.9802-1. Virta Health’s published data reports type 2 diabetes reversal rates in structured programs that measurably reduce pharmacy spend and eliminate the downstream complications driving stop-loss claims. The employer who invests $300 to $500 per member per month in a disease management program for identified high-risk members is not spending charity. They are investing against a stop-loss claim that costs $250,000 when it arrives.

The Honest Commitment

#

The employer who does right by the chronically comorbid employee makes medication adherence financially possible rather than financially punishing. Zero cost-sharing on maintenance medications. DPC for the coordination relationship. A disease management program that invests in the trajectory rather than waiting for the acute event. These decisions cost money in year one. They produce measurable savings in years two through five as medication adherence prevents the emergency utilization, the hospitalization, and the catastrophic claim that the deductible wall was generating by making prevention unaffordable.

The employer’s third objective from TOS.PRE is keep it honest. The honest accounting here is specific: the standard plan design with a $2,500 deductible applied to maintenance medications is not neutral. It is a design choice that produces worse outcomes for the sickest employees and higher costs for the plan in the aggregate. The employer who understands this and makes the three design changes identified above has not adopted a philosophy. They have read the actuarial evidence and made a different bet. The bet is that investing $150 per month in a DPC membership and eliminating the deductible on a $40 generic statin is cheaper than absorbing a $250,000 cardiac event in year three. The evidence says the bet pays. The employer who makes it is not generous. They are competent.